
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at long term treatment with 2 drugs called olaparib and cediranib for women whose ovarian cancer has started to grow again. It is for women whose cancer shrunk after their first course of chemotherapy. And they are having a second course.
The trial is open to women who have:
Doctors treat these cancers in the same way. So, when we use the term ovarian cancer in this summary, we are referring to all 3.
Cancer Research UK supports this trial.
Platinum chemotherapy is one of the usual treatments for ovarian cancer. This includes the drugs cisplatin and carboplatin. But sometimes the cancer can come back. You might then have a second course of chemotherapy if it worked well the first time.
Doctors are looking for ways to improve treatment in women with ovarian cancer. In this trial, they are looking at 2 drugs called cediranib and olaparib. They think that having this extra treatment after second course chemotherapy can help control the cancer.
Cediranib and olaparib are both types of targeted drugs. They work in different ways.
Olaparib is a PARP inhibitor. It blocks an enzyme called PARP, which helps damaged cancer cells to repair themselves. Doctors think that if they stop PARP working, the cancer cells will not be able to repair themselves.
Cediranib is a tyrosine kinase inhibitor. It stops cancers from being able to make new blood vessels that they need to grow. We know from research that having it with olaparib helps control the cancer for longer.
Some women in the trial have olaparib on its own. And some have olaparib and cediranib.
The main aim of the trial is to see if olaparib and cediranib can increase the length of time before the cancer starts to grow again.
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able join this trial if all of the following apply:
After your second course of chemotherapy, the following must also apply:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You:
Other
You:
This trial is taking place worldwide. It is a phase 3 trial. The researchers hope 618 women will take part.
Your doctor will check to see how well your second course of chemotherapy worked with a scan or blood tests. Once they have confirmed that your cancer has shrunk, and you meet all the other entry conditions, then you might be suitable to have the treatment in this trial.
It is a randomised trial. You are put into 1 of 2 groups by a computer. Neither you nor your doctor can decide which group you are in.
You have 1 of the following:
Olaparib and cediranib are tablets.
Women in Group A take:
Women in Group B take olaparib tablets twice a day.
The trial team will tell you exactly when to start taking the tablets. You have them for as long as they are working and the side effects aren’t too bad.
You stop treatment if your cancer starts to grow again. Your doctor will talk to you about other treatment options.
Quality of life
The trial team will ask you to fill out a questionnaire before you start treatment and at set times during treatment. The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
Tissue and blood samples
The trial team will look at a sample of tissue you gave when you were first diagnosed or when you had more surgery.
You have extra blood tests as part of this trial. Where possible you have these at the same time as your routine blood tests.
They will also use the samples to:
You see a doctor and have some tests before you can join the trial. These tests include:
You go to hospital:
At each visit you have blood tests, urine tests and a check up. You might also have to do a 24 hour urine collection. You take a container home and collect all the urine you pass in a 24 hour period. You then return the urine collection to the trial team.
You have a CT scan:
When you finish treatment, the trial team contact you every 3 to 6 months to see how you are getting on. They might phone you or see you at a routine hospital appointment.
The trial team will monitor you during the time you have treatment and you’ll have a phone number to call them if you are worried about anything.
The most common side effects of olaparib include:
The most common side effects of cediranib include:
The trial team will tell you all about the possible side effects before you join.
We have more information about olaparib.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Shibani Nicum
Cancer Research UK
AstraZeneca
University College London
This is Cancer Research UK trial number CRUK/15/074
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”